Analysts Set Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Target Price at $4.80

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has been given a consensus rating of “Moderate Buy” by the five analysts that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $4.80.

A number of research analysts have weighed in on the stock. Robert W. Baird dropped their target price on shares of Karyopharm Therapeutics from $8.00 to $5.00 and set an “outperform” rating on the stock in a research note on Wednesday, August 7th. Royal Bank of Canada reiterated an “outperform” rating and issued a $3.00 price objective on shares of Karyopharm Therapeutics in a research note on Wednesday, August 7th. HC Wainwright reissued a “buy” rating and issued a $7.00 target price on shares of Karyopharm Therapeutics in a research report on Wednesday, August 7th. Finally, StockNews.com raised Karyopharm Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th.

Karyopharm Therapeutics Stock Performance

Shares of Karyopharm Therapeutics stock opened at $0.74 on Tuesday. The business’s fifty day simple moving average is $0.84 and its 200 day simple moving average is $1.03. Karyopharm Therapeutics has a 12 month low of $0.62 and a 12 month high of $1.95. The firm has a market capitalization of $91.97 million, a P/E ratio of -0.58 and a beta of 0.20.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its earnings results on Tuesday, August 6th. The company reported ($0.20) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.09. The business had revenue of $42.79 million for the quarter, compared to the consensus estimate of $36.07 million. Analysts predict that Karyopharm Therapeutics will post -0.93 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of KPTI. AQR Capital Management LLC raised its holdings in Karyopharm Therapeutics by 494.5% during the 2nd quarter. AQR Capital Management LLC now owns 748,020 shares of the company’s stock valued at $649,000 after acquiring an additional 622,194 shares during the period. Cubist Systematic Strategies LLC bought a new stake in shares of Karyopharm Therapeutics during the 2nd quarter valued at $494,000. Panagora Asset Management Inc. bought a new stake in shares of Karyopharm Therapeutics during the 4th quarter valued at $197,000. Acadian Asset Management LLC bought a new stake in shares of Karyopharm Therapeutics during the 2nd quarter valued at $167,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in Karyopharm Therapeutics in the 2nd quarter worth about $143,000. 66.44% of the stock is owned by institutional investors.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).